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 30 
Abstract 31 
 32 
Introduction 33 
Trachoma, caused by the intracellular bacterium Chlamydia trachomatis (Ct) is the leading 34 
infectious cause of preventable blindness. Many commercial platforms are available that 35 
provide highly sensitive and specific detection of Ct DNA. However, the majority of these 36 
commercial platforms are inaccessible for population-level surveys in resource-limited 37 
settings typical to trachoma control programmes. We developed two low-cost quantitative 38 
PCR (qPCR) tests for Ct using readily available reagents on standard real-time 39 
thermocyclers.  40 
 41 
Methods 42 
Each multiplex quantitative PCR test targets one genomic and one plasmid Ct target in 43 
addition to an endogenous positive control for Homo sapiens DNA. The quantitative 44 
performance of the qPCR assays in clinical samples was determined by comparison to a 45 
previously evaluated droplet digital PCR (ddPCR) test. The diagnostic performance of the 46 
qPCR assays were evaluated against a commercial assay (artus C. trachomatis Plus RG 47 
PCR, Qiagen Ltd) using molecular diagnostics quality control standards and clinical 48 
samples. We examined the yield of Ct DNA prepared from five different DNA extraction kits 49 
and a cold-chain free dry-sample preservation method using swabs ‘spiked’ with fixed 50 
concentrations of human and Ct DNA.  51 
 52 
Results 53 
The qPCR assay was highly reproducible (Ct plasmid and genomic targets mean total 54 
coefficients of variance 41.5% and 48.3%, respestively). The assay detected 8/8 core 55 
specimens upon testing of a quality control panel and performed well in comparison to 56 
commercially marketed comparator test (sensitivity and specificity >90%). Optimal extraction 57 
and sample preservation methods for research applications were identified. 58 
 59 
Conclusion 60 
We describe a pipeline from collection to diagnosis providing the most efficient sample 61 
preservation and extraction with significant per test cost savings over a commercial qPCR 62 
diagnostic assay. The assay and its evaluation should allow control programs wishing to 63 
conduct independent research within the context of trachoma control, access to an 64 
affordable test with defined performance characteristics. 65 
 66 
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Introduction  68 
 69 
Chlamydia trachomatis (Ct) is the cause of trachoma, which is the leading cause of infection-70 
related blindness worldwide (1,2). Ct is also the most commonly diagnosed bacterial 71 
sexually transmitted infection (3). Diagnosis of trachoma is made by the observation of a 72 
clinical sign which is the appearance of lymphoid follicles and inflammation on the tarsal 73 
conjunctiva (4). This clinical sign is not highly specific (5) and in low-prevalence or post-74 
treatment settings can correlate poorly with for ocular Ct infection (6–8). Control programs 75 
use azithromycin mass drug administration (MDA) in trachoma endemic communities as part 76 
of an overall strategy to control transmission, but the drop in prevalence of infection results 77 
in a decrease in the positive predictive value of clinical signs of disease (8).  78 
 79 
Determination of infection load data offers additional benefits to a qualitative diagnostic 80 
assay because load of infection is associated with disease severity (5). Reference-free 81 
methods for quantitation of nucleci acids using digital droplet PCR technology have also 82 
been evaluated (9); these have been useful in demonstrating that infection load may be 83 
involved in transmission (10). In populations that have been treated en masse with 84 
azithromycin, the loads of individual infections are usually low (11). Identifying sub-85 
populations in which there are infections with higher than average loads can identify 86 
communities and subgroup ‘hotspots’ that are reservoirs of infection in otherwise trachoma-87 
free areas (12). Conversely, infections in low prevalence or post-treatment settings may not 88 
be of high enough load to sustain transmission and the community or burden of infection 89 
may decline; this is referred to as the Allee effect (7,13). A quantitative diagnostic test may 90 
therefore assist in programmatic decisions such as when to continue, cease or target 91 
azithromycin MDA (14).  92 
 93 
Nucleic acid amplification tests (NAATs) have become the gold standard for Ct-specific tests 94 
of infection, due to their superior sensitivity and throughput when compared to culture and 95 
antigen detection techniques (15). There are many accredited commercial assays for the 96 
diagnosis of sexually transmitted Ct infections but very few are evaluated for testing with 97 
ocular swabs. Diagnostic tests with quantitative capabilities, such as the Abbott RealTime 98 
CT/NG m2000 (16) platform is widely distributed in many low- and middle-income countries 99 
yet per-specimen testing costs remain beyond trachoma control and research programs.   100 
 101 
NAATs for Ct are not currently required by the international guidelines for implementation or 102 
cessation of the “SAFE” (Surgery for the correction of in-turned eyelashes, Antibiotics to 103 
treat infection, promotion of Facial hygiene and Environmental improvement to reduce 104 
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transmission) strategy for trachoma control (17). Diagnosis of current Ct infection can be a 105 
valuable component of the monitoring and evaluation of trachoma control programs (18). 106 
Where NAATs have been used, both commercial (19) and non-commercial (20,21) tests 107 
have yielded important results that have shaped the scientific agenda for control program 108 
evaluation, the research activities of government/non-government organisations and the 109 
policy of funding bodies. The cost efficacy of using a commercial NAAT to guide MDA 110 
cessation has been evaluated (22) and it was found that a low-cost commercial NAAT can 111 
be cost effective for the control program as test costs were offset by savings from the 112 
distribution of further unnecessary annual treatment rounds of MDA. In addition to the cost 113 
benefit, avoiding unnecessary rounds of MDA would reduce community antibiotic exposure 114 
and risk of emergence of antibiotic resistance. 115 
 116 
There are many situations in which an open-platform test with evaluated performance 117 
characteristics may enable valuable data to be gathered and we therefore designed and 118 
evaluated the performance of a NAAT for detection and enumeration of ocular Ct infections. 119 
The test was required to be high throughput, low cost, quantitive and comparable in 120 
performance to a commerical alternative. Capacity to multiplex targets was also important to 121 
enable concurrent testing of specimen collection and extraction. qPCR was therefore 122 
selected over other technologies suitable for low-resource settings (such as end-point PCR 123 
or loop-mediated amplification (LAMP) (23)).   124 
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Methods 125 
 126 
Study ethics  127 
 128 
Samples were collected from trachoma-endemic communities in Tanzania and Guinea-129 
Bissau as detailed below. Ethical approval for the collection of these samples was obtained 130 
from the following ethics committees; Comitê Nacional de Ética e Saúde (Guinea Bissau), 131 
London School of Hygiene and Tropical Medicine, UK. Kilimanjaro Christian Medical Centre, 132 
Tanzania and the National Institute for Medical Research, Tanzania.  The support of local 133 
leaders in every community was ascertained before sample collection began. All participants 134 
were required to provide written, informed consent prior to study enrollment and parents or 135 
guardians provided consent for children. 136 
 137 
Oligonucleotides 138 
 139 
Primer and hydrolysis probe sequences used in this study are shown in Table 1. Primers 140 
targeting highly conserved species-specific regions of plasmid open reading frame 2 141 
(pORF2) and outer membrane protein complex B (omcB) of Ct were previously described by 142 
Pickett and colleagues (24). pORF2 and omcB probe sequences were designed using 143 
Primer Express v3 (Life technologies, Paisley, UK). Oligonucleotides for use on Applied 144 
Biosystems (ABI) real time thermocyclers were synthesized by Life Technologies. 145 
Oligonucleotides for use on the Corbett Rotor-Gene (a.k.a Qiagen Rotor-Q) were 146 
synthesized by Sigma (Sigma-Aldrich, UK). Endogenous control primers and probes specific 147 
to the Homo sapiens RNase P/MRP 30-kDa subunit (RPP30) gene were previously 148 
described by Luo and colleagues (25). There is no variation in primer or probe binding sites 149 
in published Ct genome and plasmid sequences (NCBI Blastn search January 2017). omcB 150 
and pORF2 targets are present in a single copy per chlamydial genome and plasmid, 151 
respectively. Studies have estimated copy number in clinical specimens to be between 1 152 
and 18 copies per genome (26). 153 
 154 
qPCR 155 
 156 
For ABI thermal cyclers, each 10-L qPCR contained final concentrations of 1× TaqMan 157 
Universal Mastermix II, with Uracil-DNA N glycoslyase (UNG, a common method to minimize 158 
PCR cross-contamination by enzymatic  degradation of previous PCR products with 159 
incorporated dUTP; Life technologies, Paisley, UK), each oligonucleotide at 0.3 M and 2 L 160 
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template DNA in aqueous solution. In the United Kingdom, the assay was performed on an 161 
ABI 7900HT Fast Real Time PCR machine (Life Technologies, Paisley, UK). In Tanzania, 162 
the assay was performed on an Applied Biosystems ViiA 7 Real Time PCR machine (Life 163 
Technologies, Paisley, UK). Both instruments utilized a 384-well format.  164 
 165 
For Rotor-Gene thermal cyclers samples were run in a 72-well rotor format on a Corbett 166 
Rotor-Gene 3000. Each 20-µL qPCR contained 1× qPCRBIO Probe Mix No-Rox (PCR 167 
Biosystems, London, UK), each oligonucleotide at  0.3 M and 8 L template DNA in 168 
aqueous solution.  169 
 170 
No-template controls  and serial dilutions of known-concentration PCR product were 171 
included on each run on all systems. Thermal cycling conditions for all systems were 50°C 172 
for 2 minutes, 95°C for 10 minutes, followed by 45 cycles of 95°C for 15 seconds and 60°C 173 
for 60 seconds. Samples with quantitation cycle (Cq) values <15 cycles were diluted and 174 
retested. 175 
 176 
Calibration curve 177 
 178 
Calibration standards were prepared using DNA extracted from cultured Human Epithelial 179 
type-2 (HEp-2) cells, which had been infected with Ct strain A2497. The Novogen KOD PCR 180 
kit (Novogen, Sydney, Australia) was used to amplify the pORF2, omcB and RPP30 targets 181 
using the primers described in table 1. PCR products were purified and extracted using the 182 
Promega gel clean-up kit and Wizard SV PCR spin columns (Promega, Madison, WI. USA) 183 
according to manufacturer’s guidelines. PCR products were then diluted 1:107 in 1 mM Tris-184 
Cl 0.1 mM EDTA (0.1× TE) buffer on a background of 2 ng/L herring sperm DNA (Sigma 185 
Aldrich, St Louis, LA. USA). These standards were ten-fold serially diluted through ten steps 186 
to create a calibration curve. A droplet digital PCR (ddPCR) assay (26,9) was used to 187 
estimate the number of chlamydial and human targets in each standard. The limit of 188 
detection was defined as the lowest analyte concentration at which all ten repeat 189 
measurements of a specific dilution returned a positive result. 190 
  191 
Analysis of clinical samples 192 
 193 
To assess the performance of the qPCR test in clinical specimens, we compared the results 194 
of testing by artus C. trachomatis Plus RG PCR, qPCR and ddPCR. This analysis used 99 195 
randomly selected samples from a collection of clinical ocular-swab derived DNA specimens 196 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Running title: Chlamydia trachomatis qPCR   
 
   8 
that originated from a 2014 study of children aged 1-9 years selected from trachoma-197 
endemic communities on the Bijagos Islands, Guinea-Bissau. Sample collection protocols 198 
and Ct ddPCR results were described previously (27). In Tanzania we also tested 523 199 
samples with qPCR referenced against ddPCR. These clinical samples were from a single 200 
cross-sectional time point of a 4-year longitudinal study of a cohort of children aged 5–10 201 
years of age. In each study, samples were collected prior to community treatment with 202 
azithromycin.  203 
 204 
The artus C. trachomatis Plus RG PCR Kit (96) CE (4559265) was used to test the samples 205 
from the Guinea-Bissau cohort. Testing was performed as per manufacturer’s instructions 206 
using the kit internal control to monitor possible PCR inhibition by adding directly to the 207 
reaction mixture. 208 
 209 
Quality control molecular diagnostics panel performance 210 
 211 
Using the assays described above, we used an external quality control molecular 212 
diagnostics panel of samples, (Quality Control in Molecular Diagnostics (QCMD) programme 213 
(www.qcmd.org) (28)). The panel consisted of positive and negative samples which 214 
participants were expected to detect (termed ‘core’ samples) and low-load samples termed 215 
‘educational’ that contained <1 genome equivalent per microlitre of sample. In ‘educational’ 216 
specimens, the load is so low that only extremely sensitive tests (i.e. those using target 217 
enrichment or transcription-assisted amplification) would be expected to routinely identify 218 
these as positive. The lyophilized samples were rehydrated according to QCMD protocol, in 219 
4 mL of sterile molecular biology-grade water, of which DNA was extracted from 1 mL and 220 
eluted into 100 L. Following DNA extraction, the assays were performed as described.  221 
 222 
Testing costs of extracted DNA from clinical swabs by artus C. trachomatis Plus RG PCR, 223 
qPCR and ddPCR 224 
 225 
The laboratory cost of processing the samples by each assay was calculated for both 226 
personnel time and consumables. Costs of consumables were taken from current UK list 227 
prices at the time of publication and were expressed in US Dollars (US$). Personnel costs 228 
were based on a salary for a junior labortory technician at Kilimanjaro Christian Medical 229 
Centre in Moshi, Tanzania. Per-sample costs were calculated based on the time taken to 230 
complete one run on each analysis platform and then expressed as a per sample cost 231 
including overheads. Equipment procurement costs were not included in the analysis, as 232 
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thermocycler availability and use will vary between country and laboratory. However, prices 233 
for the thermocyclers used in this manuscript are stated in the footnote for Table 6. 234 
 235 
Preparation of ‘spiked’ swabs for use in storage assessment experiments 236 
 237 
A suspension of cultured HEp-2 cells and serovar A Ct EBs in phosphate-buffered saline 238 
(PBS) was inoculated onto swabs. HEp-2 cells were spiked into PBS at approximately 239 
400,000 per 1 mL of PBS. Elementary bodies (EBs) were spiked into the same suspension 240 
at a dilution of 2 L of EBs per 1 mL of PBS to achieve a high concentration of Ct targets per 241 
PCR reaction.  The suspension was homogenized and 50 L was aliquoted onto polyester-242 
coated swabs (Puritan Medical Products, Guilford, USA). Swabs were allocated to storage in 243 
one of three conditions: dry storage in polystyrene tubes at room temperature (uncontrolled, 244 
typically 22-25C), dry storage in paper envelopes at room temperature inside a domestic 245 
vacuum-sealed container with silica desiccant, or dry storage in polystyrene tubes at -20C. 246 
Four swabs were prepared and processed per time point per storage condition. Swabs were 247 
removed from storage at 7, 30, 90 and 180 days and DNA was extracted using the swab 248 
protocol of the QIAamp DNA mini kit (Qiagen, Manchester, UK) according to manufacturer’s 249 
instructions. Swabs were tested using ABI qPCR.  250 
 251 
Comparison of DNA extraction kits and recovery of Chlamydia trachomatis nucleic acids 252 
 253 
Peripheral blood mononuclear cells (PBMCs) were extracted from the blood of a healthy 254 
volunteer. PBMCs were suspended in PBS and aliquots spiked with high, medium and low 255 
loads of Ct A/2497 elementary bodies (EBs). One aliquot did not have any EBs added to act 256 
as negative control. A 50-µL aliquot of suspension was pipetted directly onto swabs. A total 257 
of 25 swabs were prepared at each concentration level and refrigerated overnight. Five 258 
swabs were selected at random from each concentration group. Each swab was rehydrated 259 
in 400 µL of PBS. They were then vortexed at full speed for 2 minutes and the swab was 260 
removed and discarded, expressing any excess liquid on the side of the tube. DNA was then 261 
prepared following the manufacturer’s recommendations for each respective kit. The elution 262 
volume was standardised to 100 µL.  Five extraction kits were compared: MTB Isolation 263 
(Elisabeth Pharmacon), Blood and Serum DNA Isolation Kit (BioChain), Cador Pathogen 264 
(QIAGEN), QIAamp Mini DNA Extraction (QIAGEN) and Power Soil DNA Isolation Kit 265 
(MoBio), which includes a mechanical lysis step (specimen lysed in PowerBead tube at 6 266 
m/s for 40 seconds).  Four 1 µL aliquots of eluate were tested per swab, resulting in 20 test 267 
wells per condition. Cq values from high-, medium- and low-load sample eluates were 268 
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collated into a single dataset for each extraction kit. QIAmp DNA mini kit was used as our 269 
standard reference as it is used widely in many studies, and our group has used this kit 270 
extensively in trachoma studies (9,29,30).  271 
 272 
Data analysis 273 
 274 
Data were reported in accordance with Minimum Information for Publication of Quantitative 275 
Real-Time PCR Experiments (MIQE) guidelines (31) (see supplementary information). 276 
Clinical specimens and PCR product dilutions were classified as positive for Ct if the test 277 
detected amplification of the plasmid target in any well within 40 cycles for the ABI assay, or 278 
35 cycles for the Rotor-Gene assay. The load of infection was determined by extrapolation 279 
from an eight-step, ten-fold dilution of PCR product standards of known concentration; these 280 
were tested in triplicate on each plate. 281 
 282 
SDS 2.4 software (Life Technologies, Paisley, UK) was used for data analysis. Baseline 283 
fluorescence intensity values were determined by analysis of mean fluorescence between 284 
cycles 3 and 15 on both platforms. The Cq boundary line was set at 0.2 for all three 285 
fluorescence channels (FAM/VIC/NED) on the ABI instrument, and at 0.1 on the Rotor-Gene 286 
instrument. Cq data were exported from SDS 2.4 and further analysed using R version 3.2.2 287 
(32). Linear regression was used to determine whether the Cq decreased significantly with 288 
time under different storage conditions. The gradients of linear models were examined to 289 
determine whether a significant downward trend was identified. To determine if there were 290 
significant differences between Ct DNA recovery from extraction kits, homogeneity of 291 
variance within the total dataset was assessed using Fligners test. One-way Analysis of 292 
Variance (ANOVA) with Tukey’s Honest Significant Difference (HSD) post-hoc test was used 293 
to determine which of the observed differences were significant. 294 
  295 
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Results  296 
 297 
Assay performance  298 
 299 
The assay characteristics derived from repeat testing of a standard curve are presented in 300 
Table 2. The experimentally determined dynamic range of the assay was between 1 and 1 x 301 
106 copies of omcB and/or pORF2 per reaction. The coefficients of determination for all 302 
three targets in both assays was greater than 0.99. Amplification of all targets was highly 303 
(>95%) efficient. omcB, pORF2 and RPP30 were reproducibly detected at concentrations of 304 
0.9–8.3 copies per test, but not below. No-template controls tested negative on every run. 305 
 306 
The mean coefficient of variance around all data points across the whole dynamic range was 307 
48.3% for the omcB target, and 41.5% for the pORF2 target, approximately equivalent to 0.6 308 
and 0.5 PCR cycles, respectively. For the Rotor-Gene assay, the coefficient of variance was 309 
35.3% for omcB and 20.3% for pORF2, equivalent to approximately 0.4 and 0.3 cycles, 310 
respectively. The largest contributor to assay variance on both platforms was between-run 311 
variation. The coefficient of variance generally increased at lower concentrations, possibly 312 
reflecting the increased chance of smapling handling error where analytes are rare. 313 
Interestingly, when Cq values were compared between ABI 7900HT and ABI Viia7 314 
machines, the assay parameters were mostly similar with the exception that absolute omcB 315 
Cq values were consistently between 0.5 and 1.5 cycles higher when tested in Tanzania than 316 
when tested in the UK.  317 
 318 
Quality control panel performance 319 
 320 
All three assays (artus, ABI and Rotor-Gene) performed well when used to test external 321 
quality control molecular diagnostics samples, correctly diagnosing 8/8 (100%) of ‘core’ 322 
samples.  Two low-load ‘educational’ samples, which were below the measured limit of 323 
reproducible detection for the assay were not classified as positive. The results are shown in 324 
Table 3.  325 
 326 
Clinical specimens 327 
 328 
According to the validated commercial kit (artus), 28/99 Guinea Bissau specimens were 329 
positive for Ct. The mean Cq of those positive specimens was 30.3. On the ABI platform 330 
26/99 of the Guinea Bissau samples were positive. Of the same sample set, 23/99 samples 331 
tested positive by Rotor-Gene. Of the artus-positive results, only one was negative by all 332 
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other methods. The load estimates from samples where both targets were detected is shown 333 
in Figure 1. omcB was not detected in two of the ABI positive specimens, which had a 334 
plasmid load of 2 and 3 copies/L, respectively. The median artus Cq of artus+ qPCR- (false 335 
negative) specimens was 34.9 and 32.4 cycles for the ABI and Rotor-Gene assays, 336 
respectively (figure 1). The median load of artus- qPCR+ specimens was 29 and 3 copies/L 337 
for the ABI and Rotor-Gene assays, respectively. For omcB, the median load of the ddPCR+ 338 
qPCR- samples was 1.2 and 0.7 copies/L for the ABI and Rotor-Gene platforms, 339 
respectively (figure 2). There were no ddPCR- qPCR+ samples. 340 
 341 
In Tanzania we tested a further 523 clinical samples by ABI qPCR that had also been tested 342 
by ddPCR at LSHTM. The overall prevalence of infection by ddPCR was 12.4% (65/523). By 343 
qPCR there were 78/523 positive samples leading to a sensitivity and specificity of 100% 344 
(95% CI 94.5 – 100) and 97.2% (95% CI 95.2 – 98.5). The data are shown in Table 4. 345 
 346 
Comparative efficiency of sample extraction and yield 347 
 348 
DNA prepared using the PowerSoil DNA kit yielded the most variable estimates of Ct burden 349 
overall (Figure 3). Qiagen Cador and Biochain kits recovered the highest amounts of Ct DNA 350 
measured by the quantity of  omcB  (p = 0.001 and p = 0.0004, respectively) and pORF2 (p 351 
= 0.0004 and p = 0.002, respectively) load compared to QIAmp DNA mini extraction. Using 352 
one-way Analysis of Variance (ANOVA) was considered appropriate as there was no 353 
significant heterogeneity in the variance between comparator groups (Fligner’s test (omcB p 354 
= 0.31 and pORF2 p = 0.66)). There were significant differences within the model for both 355 
targets (omcB p = 0.00005 and pORF2 p = 0.00003).  Pair-wise analyses using Tukey’s 356 
Honest Significant Difference (HSD) post-hoc test, found that both Qiagen Cador and 357 
Biochain kits had significantly higher yield when compared to MTB, QIAmp DNA mini and 358 
PowerSoil DNA kits. The results of the pair-wise comparisons were consistent for both omcB 359 
and pORF2 targets. 360 
 361 
Sample preservation and storage 362 
 363 
Ct and human DNA was readily detectable in all samples at all time points, with no 364 
diagnostic failures by 6 months storage at room temperature (Figure 4). All three treatments 365 
showed a significant increase in Cq required to detect Ct over 6 months according to linear 366 
regression models, indicating a decrease in target abundance (Table 5). Based on these 367 
models the estimated rate of reduction in detectable load was 0.01-0.02% of the 7-day 368 
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specimen Cq per day. After 6 months, the mean Cq for detection of plasmid had increased by 369 
18% for the frozen swabs, and by 21% and 14%, respectively, for the desktop and vacuum 370 
contained room temperature swabs. The Cq for omcB target detection had increased by 9% 371 
for the frozen swabs, and by 17% and 14%, respectively, for the desktop and vacuum 372 
contained room temperature swabs.  373 
 374 
Testing costs of extracted DNA from clinical swabs by artus C. trachomatis Plus RG PCR, 375 
qPCR and ddPCR 376 
 377 
Overall costs and component parts can be found in Table 6. The commercial test artus was 378 
the most expensive at $25.04 per sample, and the least expensive was the Rotor-Gene at 379 
$9.51 per sample. Calculated costs include trained laboratory technician time for a 380 
Tanzanian Junior Laboratory Technician and therefore all testing runs can be prepared 381 
within a reasonably short period of time. A single ABI qPCR plate of up to 88 samples run 382 
with four technical replicates (plus standards) takes an experienced operator approximately 383 
1.5 hours to prepare and 1.75 hours to run. The operator time is increased for ddPCR to 2 384 
hours preparation time for up to 94 single reaction samples and 2.5 hours run time. Time 385 
savings can be found in the use of the Rotor-Gene which takes approximately 1 hour to 386 
prepare and 1 hour to run 63 single reaction samples. The latter is comparable to the time 387 
required to test 70 samples by artus.   388 
 389 
390 
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Discussion  391 
 392 
We evaluated a qPCR assay that detects Ct plasmid and genomic targets, whilst assessing 393 
specimen sufficiency with the presence of human DNA. The assay has a linear analyte 394 
response for all three targets that is reproducible across a wide dynamic range (1 - 106 395 
copies/test) of both plasmid and chromosomal targets. The limits of reproducible detection 396 
for both Ct targets are below 10 targets per test, which is comparable to other non-397 
commercial PCR tests (24,33). The absolute sensitivity of the omcB and pORF2 tests is 398 
similar, however, due to the relative abundance of the plasmid target in clinical specimens, 399 
the plasmid test detects a lower absolute number of chlamydial equivalents and therefore 400 
has a superior diagnostic performance.  401 
 402 
The total assay variance within-centre was consistently <1 PCR cycle. There was significant 403 
variation within-run (omcB mean: 24.7%, pORF2 mean: 19.5%), suggesting that, where 404 
precise quantitation is required, specimens should ideally be run in multiple wells. Where a 405 
qualitative diagnostic result is sufficient, running assays in a single well would only result in 406 
diagnostic failure due to assay variability at very low loads. The between-laboratory variance 407 
is higher, which could be attributed to instrument differences between the 7900HT and the 408 
Viia 7 (laser excitation versus halogen light source), however the assay was highly linear on 409 
both platforms and the total variance on either target was <1.5 cycles.  410 
 411 
External quality control exercises that included masked testing were used to evaluate these 412 
qPCR assays. During this exercise we successfully identified Ct infection in a specimen that 413 
carried a well-characterised plasmid deletion (34) (table 4). An endogenous control target 414 
confirms that the specimen comes from a human and has been stored and processed in a 415 
way that has not compromised the DNA quality therefore  differentiating between infection 416 
negative tests and assays that have failed through PCR inhibition or absence of a testable 417 
DNA analyte.  418 
 419 
Diagnostic performance compared to a commercially marketed Ct diagnostic kit (artus C. 420 
trachomatis Plus RG) was good, offering sensitivity and specificity >90%. The median load 421 
of the false negative specimens was much lower than the load of the dual positive 422 
specimens, with the exception of one specimen detected by artus with a Cq of 23 cycles that 423 
was not detected by ddPCR or either qPCR assay. Agreement between assays was not 424 
perfect for any of the tested pairings between ddPCR, qPCR and artus.  425 
 426 
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Comparative omcB load analysis between the qPCR assay and ddPCR assay showed high 427 
concordance, with discordant results occurring at or below the limit of detection of the qPCR 428 
assay. At such low concentrations, sampling volume limitation impacts on the reproducibility 429 
of a positive result. Targets are sporadically detected in samples where the analyte 430 
concentration is below the limit of detection and the likelihood of a positive and negative 431 
result is limited by dilution/concentration and fits a poisson distribution (35).  432 
 433 
Assuming the level of technical replication described in this paper and UK list prices from 434 
2017, the qPCR assay costs roughly $11.51 per sample, inclusive of DNA extraction ($3.75). 435 
Whereas testing using the commercial kit artus, costs more than twice as much at $25.05 436 
per sample. Reducing the number of technical replicates, reducing the volume of the assay 437 
to 5 L, or omitting primer–probe sets for nondiagnostic targets (omcB or RPP30) could 438 
reduce the overall cost of the assay further, whilst the use of a larger DNA aliquot could 439 
offset potential loss of sensitivity. Use of the Rotor-Gene and ddPCR platform allows a larger 440 
sample volume to be assayed in a single reaction and is competively costed against artus at 441 
respectively $9.51 and $15.64 per sample. Proprietary fluorophores may also be 442 
interchanged for non-proprietary equivalents to reduce cost or enable the assay to run on 443 
real-time thermocyclers from other manufacturers. 444 
 445 
Along with other NAAT methods, qPCR is a useful research tool. In this study we utilize 446 
qPCR for three key purposes: (1) to determine the loss of material during extraction under 447 
differing conditions, (2) to determine the rate of degradation of DNA under different long-448 
term storage conditions and (3) to analyse the concentration of diagnostic discrepant results. 449 
The BioChain extraction kit performed best in this study. For sample storage room 450 
temperature preservation rather than frozen, regardless of of dessication method, did not 451 
increase the rate of loss of detectable Ct DNA suggesting that control programs without 452 
access to a freezer may be able to store swabs at room temperature without loss of 453 
diagnostic perfomance. This has previously been described for Ct stored for long periods in 454 
transport media, and in short-term dry storage at room temperature (36,37).  455 
 456 
Together, these findings describe an optimal pipeline of sample handling and processing in 457 
a budget-conscious research setting. By demonstrating variability at each step of the 458 
pipeline, this study illustrates the flexible nature of qPCR that allows parameters to be 459 
modified according to user requirement (38). The qPCR method described may offer an 460 
effective and affordable solution for quantitative estimates of Ct loads in trachoma studies. 461 
462 
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Table 1. Olignucleotides used in this study. 604 
 605 
 606 
  607 
Target Oligo 
Sequence (5'-3') 
Amplicon 
size (bp) 
C. trachomatis 
omcB 
Primer (F)
†
 GAC ACC AAA GCG AAA GAC AAC AC 
106 
Primer (R)
†
 ACT CAT GAA CCG GAG CAA CCT 
ABI – Probe
§
 
[FAM]-CCA CAG CAA AGA GAC TCC CGT AGA CCG-
[QSY] 
Rotor-Gene - 
Probe§ 
[FAM]-CCA CAG CAA AGA GAC TCC CGT AGA CCG-
[BHQ] 
 
C. trachomatis 
pORF2 
Primer (F)
†
 CAG CTT GTA GTC CTG CTT GAG AGA 
109 Primer (R)
†
 CAA GAG TAC ATC GGT CAA CGA AGA 
ABI Probe
§
 [NED]-CGG GCG ATT TGC CTT-[MGBNFQ] 
Rotor-Gene - 
Probe§ 
[JOE]-CCC CAC CAT TTT TCC GGA GCG A-[BHQ1]  
H. sapiens RPP30 
Primer (F)
†
 AGA TTT GGA CCT GCG AGC G 
65 Primer (R)
†
 GAG CGG CTG TCT CCA CAA GT 
ABI - Probe
§
 [VIC]-TTC TGA CCT GAA GGC TCT GCG CG-[QSY] 
 
Rotor-Gene – 
Probe
§
 
[Cy5]-TTC TGA CCT GAA GGC TCT GCG CG-[BHQ2] 
 
Bp: base pairs;  F: forward; omcB: outer membrane complex B; pORF2: plasmid open reading frame 2;  R: reverse; 
RPP30: RNase P/MRP 30-kDa subunit;  
† 
Primers purified by desalting;  
§
 Probes purified by high-performance liquid chromatography. 
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Table 2: Assay characteristics derived from repeat-tested standard curve. 608 
 609 
  610 
Assay Target CoV Gradient CoD Efficiency LoD  
Cq range at 
LoD 
ABI 7900HT 
pORF2 41.5 -3.4 0.990 96.7 8.3 34.9–37.0 
omcB 48.3 -3.3 0.998 100.1 4.5 37.4–39.7 
Rotor-Gene 
3000 
pORF2 20.3 -3.3 0.999 100.2 0.9 30.0–31.1 
omcB 35.3 -3.3 0.999 100.2 1.4 31.5–32.6 
Cq: quantitation cycle; CoD: coefficient of determination; CoV: coefficient of variance; LoD: limit of detection in 
copies/reaction; omcB: outer membrane protein complex B; pORF2: plasmid open reading frame 2 
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Table 3. External Quality Assessment panel performance of qPCR assays. 612 
Sample 
ID 
Sample Sample type QCMD 
concentration 
(copies/mL) 
artus 
Qualitative 
result 
ABI-qPCR 
Qualitative 
result 
Rotor-Gene 
Qualitative 
result 
CTA13-01 Ct
+
 urine Core Positive 
(250) 
Positive Positive Positive 
CTA13-02 Ct
+
 urine Educational Positive 
63 
NOT 
DETERMINED  
Negative Positive 
CTA13-03 nvCt
+ 
urine Core Positive 
10,000 
Positive Positive Positive 
CTA13-04 Ct
+
 urine Core Positive 
1000 
Positive Positive Positive 
CTA13-05 Ct
-
 urine Core Negative 
0 
Negative Negative Negative 
CTA13-06 nvCt
+
 urine Core Positive 
10,000 
Positive Positive Positive 
CTA13-07 Ct
+ 
swab Educational Positive 
13 
Positive Negative Positive 
CTA13-08 Ct
-
 swab Core Negative  
0 
Negative Negative Negative 
CTA13-09 Ct
+ 
swab Core Positive 
250 
Positive Positive Positive 
CTA13-10 Ct
+ 
swab Core Positive 
63 
Positive Positive Positive 
  Core performance  8/8 8/8 8/8 
  Educational 
performance 
 2/2 0/2 2/2 
Ct: Chlamydia trachomatis 
  613 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Running title: Chlamydia trachomatis qPCR   
 
   25 
Table 4. Diagnostic comparison of noncommercial qPCR assays to commercially marketed 614 
comparator. 615 
  616 
 artus C. trachomatis Plus RG PCR 
versus 
qPCR 
(ABI 7900HT) 
qPCR  
(Rotor-Gene 3000) 
ddPCR 
(Bio-Rad QX100) 
Sensitivity 90 (73.5 – 97.9) 90.6 (75 – 98) 90.6 (75 – 98) 
Specificity 97.3 (96.0 – 99.7) 94.6 (86.7 – 98.5) 94.6 (86.7 – 98.5) 
PPV 93.1 (77.4 – 98.6) 87.9 (73.5 – 95) 87.9 (73.5 – 95) 
NPV 96 (89.2 – 98.6) 95.9 (88.8 – 98.6) 95.9 (88.8 – 98.6) 
Cohens Kappa 0.82 0.78 0.83 
NPV: Negative predictive value; PPV: positive predictive value 
 617 
 618 
  619 
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Table 5: Coefficients from linear regression models examining the relationship between cycle threshold and time 623 
in days 624 
 625 
Treatment Ct pORF2 Ct omcB 
Gradient p-value Gradient p-value 
Dry, frozen 0.019 < 0.0001 0.011 < 0.0001 
Dry, desktop, room temperature 0.018 < 0.0001 0.018 < 0.0001 
Dry, vacuum box, room temperature 0.015 < 0.0001 0.016 < 0.0001 
 626 
 627 
 628 
  629 
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Table 6: qPCR assay costs 631 
 632 
Costing Category Assay Platform Cost (US$) 
artus ABI ddPCR Rotor-Gene 
DNA Extraction (kit & consumables) 4.70 4.70 4.70 4.70 
PCR Reaction mix (inclusive of oligos) 17.18 1.70 2.84 1.10 
Lab Consumables 0.41 0.12 1.84 0.35 
Personnel monthly salary Multiplied by 1.2 for 
overheads and divided by 160 for hourly rate (based on 
a trained laboratory technician from Moshi, Tanzania) 
3.37 5.06 6.74 3.37 
Total $25.04 $11.51 $15.64 $9.51 
 633 
NOTE: Purchase equipment costs for an ABI 7900HT, Rotor-Gene Q 5plex (equivalent to the 3000 which is no 634 
longer available for purchase) and ddPCR working platform are $62,445, $38,142 and $115,154 635 
respectively. 636 
 637 
  638 
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Figure 1. Comparison of plasmid load estimate from qPCR compared to artus cycle 639 
threshold. (A). ABI 7900HT. (B). Rotor-Gene 3000. The main plots show concordant results 640 
(ABI n = 24, Rotor-Gene n = 20), side panels show discordant results.   641 
ND: Not detected. 642 
 643 
Figure 2. Agreement between load estimates from ddPCR and qPCR. (A) ABI 7900HT. (B) 644 
Rotor-Gene 3000. Main panels show concordant results, side bars show discrepant results. 645 
ND: Not detected. 646 
 647 
 648 
Figure 3. Recovery of (A) omcB and (B) pORF2 from Ct-spiked swabs by five different 649 
extraction kits. Boxes represent median, inter-quartile range and range of all swabs for each 650 
treatment. Circles represent swabs spiked with high-load elementary bodies, triangles 651 
represent medium-load spiking, and crosses represent low-load spiking. There is variation in 652 
the number of targets recovered by different extraction kits. Biochain and Qiagen cador kits 653 
appear to yield more Ct DNA than comparators. 654 
 655 
Figure 4: Change in recovered load of (A) Ct plasmid and (B) genomic targets following long-term storage frozen 656 
and at room temperature. Points represent mean of four swabs per time point per condition. Dashed lines 657 
represent linear regression model between load and time. 658 
 659 
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